ABSTRACT
PURPOSE: Serum eye drops have been successfully used in the treatment of severe ocular surface disorders. Fresh frozen plasma (FFP) and platelet concentrates have not yet been tested for use as eye drops, although they are easily available as quality-controlled products from blood banks and are routinely used for transfusion. To test whether FFP or platelet-derived growth factor solutions could be used for ocular surface diseases, we compared the epitheliotrophic capacity of platelet releasate and FFP with that of serum in cell culture models. METHODS: The concentrations of EGF, TGF-beta1, PDGF-AB, fibronectin, vitamin A and vitamin E in serum, FFP, and platelet releasate were evaluated with ELISA and HPLC. Corneal epithelial cells were incubated with the various preparations and cell proliferation, migration, and differentiation were evaluated by means of a luminescence-based adenosine triphosphate (ATP) assay, a colony dispersion assay, and scanning electron microscopy. RESULTS: Growth factor concentrations were significantly higher in platelet releasate than in serum and were lowest in FFP. Fibronectin and vitamins were found in higher concentrations in serum than in FFP and were lowest in platelet releasate. Cell proliferation was best supported by platelet releasate followed by serum and FFP; however, cell migration and differentiation were better supported by serum than by platelet releasate and FFP. The reduced nutrient capacity of FFP was in part found to be due to an antiproliferative effect of citrate used as an anticoagulant in the production process. CONCLUSIONS: Platelet releasate but not FFP may offer additional potential for the treatment of severe ocular surface disease. Platelet releasate may be suitable as a novel treatment option for ocular surface disease with a superior effect on cell growth.
Subject(s)
Blood Platelets/physiology , Epithelium, Corneal/metabolism , Plasma/physiology , Serum/physiology , Wound Healing/physiology , Animals , Blood Platelets/chemistry , Blood Proteins/analysis , Cell Culture Techniques , Cell Differentiation/physiology , Cell Movement/physiology , Cell Proliferation , Corneal Diseases/drug therapy , Epithelium, Corneal/cytology , Growth Substances/analysis , Humans , Male , Microscopy, Electron, Scanning , Middle Aged , Plasma/chemistry , Rabbits , Serum/chemistryABSTRACT
BACKGROUND: Topical application of serum eye drops has been reported to accelerate healing of persistent ocular surface defects. It is supposed that growth factors in serum support the wound healing process. Platelets (PLTs) are rich in growth factors and easily available as PLT concentrates (PCs) from blood banks. Therefore, growth factor preparations from PCs may serve as a new and superior therapeutic agent for such defects. STUDY DESIGN AND METHODS: After thrombin stimulation for growth factor release, the cell-free supernatant (PLT releasate) of washed PCs (n = 8) was analyzed for epitheliotrophic factors and its wound healing capacity in comparison to serum (n = 8). Human corneal epithelial cells were used as a model to investigate cell growth, migration, and differentiation in response to both blood products. RESULTS: PLT releasate contains more epithelial growth factor, PLT-derived growth factor, and transforming growth factor-beta, but less hepatocyte growth factor, fibronectin, and vitamins. Cell growth was significantly better in response to PLT releasate. Migration and differentiation were slightly better supported by serum. CONCLUSION: Possibly owing to its high content of growth factors, PLT releasate has a distinct superior effect on cell growth. Stimulation of migration and differentiation was slightly inferior but still acceptable. PLT releasate could therefore be a novel treatment option for ocular surface defects.
